- Recce Pharmaceuticals (RCE) provides an update in the clinical trial of RECCE 327 (R327) for the treatment of burn wound infections
- RCE reports broad spectrum antibiotic activity on bacterial burn wound infections with a visible infection reduction within 24 hours on all patients
- Additionally, all acute infections were cleared within 5 days, and chronic infections within 7 days, with clinicians able to reduce treatment window
- The study at Fiona Stanley Hospital in WA is ongoing, with the targeted patient enrolment expected by early 2022 — allowing for the full data set to be compiled
- RCE shares are up 11.6 per cent at 96 cents each in morning trade
Shares in Recce Pharmaceuticals (RCE) have spiked amid a positive update in the clinical trial for the treatment of burn wound infections.
The healthcare stock is carrying out a Phase I/II clinical trial of RECCE 327 (R327) on infected burns at Fiona Stanley Hospital in Perth, Western Australia.
RCE today reported broad spectrum antibiotic activity on bacterial burn wound infections, with a visible infection reduction within 24 hours on all patients under the trial.
Additionally, all acute infections have been cleared within 5 days, and chronic infections within 7 days, with clinicians able to effectively reduce the treatment window.
Commenting on the trial, Study Investigator Ed Raby said these initial results from R327 were extremely pleasing.
“We are highly encouraged by the initial success of R327 in this topical Phase I/II trial. Patients with burn wounds often suffer severe bacterial infections that are painful, prevent wound healing and can even result in death if not properly treated,” Dr Raby said.
“Because many of these bacteria are resistant to most available drugs, we are pleased by the potential in R327 offering a treatment option for patients in need.”
Recce’s R327 study at Fiona Stanley is ongoing, with the targeted patient enrolment expected by early 2022 — allowing for a full data set to be compiled.
Company CEO James Graham said more results would be announced soon.
“We are pleased with the progress of our lead compound, R327 in patients harbouring serious burn wound infections,” he said.
“This initial update builds upon strong pre-clinical data demonstrating fast and efficient killing activity against common and problematic bacterial strains, and we are excited for the potential of R327 in the clinic.
“We look forward to updating shareholders of further human clinical data points as this trial progresses.”
Recce Pharmaceuticals securities were trading up 11.6 per cent at 96 cents each at 11:06 am AEDT.